Healthcare Innovations: WeightWatchers' Amazon Deal and Glaukos' FDA Approval

WeightWatchers partners with Amazon to streamline delivery of weight-loss drugs, boosting its stock by 9%. Meanwhile, Glaukos receives FDA approval for a new eye therapy offering a less painful treatment option, increasing its shares by 2.6%. These developments highlight significant advancements in health and telemedicine.

WeightWatchers teams up with Amazon to offer seamless delivery of weight-loss drugs, leveraging Amazon's pharmacy services. This strategic partnership is expected to benefit WeightWatchers financially as it simplifies medication fulfillment for customers, with the company's shares surging by 9% in response.

In other health news, Glaukos Corp has received FDA approval for a new eye therapy that provides a less painful treatment alternative for a progressive eye condition. This approval has positively impacted the company's market performance, with shares seeing a 2.6% increase in premarket trading.

These advancements underscore the ongoing transformations within the healthcare industry, emphasizing the growing role of telemedicine and innovative treatments in enhancing patient care.